All In Biotech

Drug Trial Radar · NCT05778188

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

A Phase 2/3, Two-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia With Long-Term Follow-Up

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 173 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

173

Planned (sponsor's estimate)

Start

Jul 27, 2023

Primary completion

Dec 2026

Study completion Dec 2028

Sponsor

Lead sponsor
ReAlta Life Sciences, Inc.Industry
Sponsor type
Industry
Collaborators
Premier Research
First posted
Mar 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 10 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the efficacy, safety, and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.

Conditions

  • Hypoxic-Ischemic Encephalopathy

Interventions

  • RLS-0071Drug

    RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.

  • PlaceboDrug

    Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Extent of acute brain injury at Day 4 (+3), assessed through magnetic resonance imaging (MRI), using a standardized scoring systemTime frame: Day 4 (up to Day 7)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site 016

    Little Rock, Arkansas · Recruiting

  • Study Site 013

    Orange, California · Recruiting

  • Study Site 020

    San Diego, California · Recruiting

  • Study Site 019

    San Diego, California · Recruiting

  • Study Site 027

    Aurora, Colorado · Recruiting

  • Study Site 001

    Gainesville, Florida · Recruiting

  • Study Site 018

    Miami, Florida · Recruiting

  • Study Site 010

    Orlando, Florida · Recruiting

  • Study Site 014

    Indianapolis, Indiana · Recruiting

  • Study Site 012

    Lexington, Kentucky · Withdrawn

  • Study Site 025

    Louisville, Kentucky · Recruiting

  • Study Site 029

    Boston, Massachusetts · Recruiting

  • Study Site 002

    Boston, Massachusetts · Recruiting

  • Study Site 006

    St Louis, Missouri · Recruiting

  • Study Site 024

    Manhasset, New York · Recruiting

  • Study Site 023

    New Hyde Park, New York · Recruiting

  • Study Site 028

    New York, New York · Recruiting

  • Study Site 003

    Durham, North Carolina · Recruiting

  • Study Site 021

    Cleveland, Ohio · Recruiting

  • Study Site 022

    Fort Worth, Texas · Recruiting

  • Study Site 030

    Houston, Texas · Recruiting

  • Study Site 005

    Morgantown, West Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.